Polymer Nanoparticles Used as Drug Carriers Characterized Using Nanoparticle Tracking Analysis
News Feb 12, 2013
This work is being carried out at Saarland University, Saarbrücken in Germany by Dr Christian Ruge and his colleagues.
In the world of pharmaceutical sciences, a detailed and full characterization of particles synthesized as drug carrier systems is indispensable. The particle size is a crucial parameter to be monitored as this will affect the stability of formulations. It will also impact with respect to size-dependent effects in biological experiments, such as the uptake of drug systems by cells.
Nanoparticle Tracking Analysis is used as a complementary tool to a Malvern Zetasizer to characterize the nanoparticles prepared by Dr Christian Ruge, a research scientist in the Department of Biopharmaceutics and Pharmaceutical Technology in the group of Professor Claus-Michael Lehr. The particles are mainly polymer-based and typically in the size range from 100 nm to 400 nm. Especially when studying samples of moderate polydispersity (i.e. with a polydispersity index, PDI, of larger than 0.2), the group uses the NanoSight system to measure the preparations to identify particle populations which are not resolved by the Malvern system.
Talking of the benefits of using NTA rather than techniques such as scanning electron microscopy, SEM, or dynamic light scattering, DLS, Dr Ruge commented, "The fact that the system is performing particle-by-particle-based measurements is a huge advantage, especially in terms of its resolving power. The fact that the instrument gives a concentration value is very useful. I feel that "visualization" of the particles based on their scattered light gives more "insight" as to the sample and its behaviour. I personally find that it is more fun working with the NanoSight instrument compared to the Zetasizer. The interaction with the instrument and being able to visualize the individual particles makes it less of a "black box" instrument and more "interesting" for me as a scientist to use. Also, I have found that during demonstrations for students, the NanoSight appears to be more transparent and thus better suited for educational purposes."
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of LondonNews
The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE